Category: FDA & Regulatory Policy (Page 2)

April 4, 2017

Alliance’s Bens Offers Testimony on User Fee Programs before Senate HELP Committee

Today, the Alliance for Aging Research's (Alliance) Vice President of Public Policy Cynthia Bens testifies before the U.S. Senate HELP Committee on reauthorization of the Prescription Drug User Fee Act (PDUFA) and the Medical Device User Fee Act (MDUFA).
April 3, 2017

Alliance Statement on Nomination of Dr. Scott Gottlieb for FDA Commissioner

Alliance for Aging Research President and CEO Susan Peschin, MHS, has issued a statement in support of the nomination of Scott Gottlieb, M.D., to be commissioner of the U.S. Food and Drug Administration (FDA).
March 28, 2017

Alliance’s Bens Offers Testimony on MDUFA before House Committee

Today, the Alliance for Aging Research's Vice President of Public Policy Cynthia Bens testifed before the U.S. House of Representatives' Energy and Commerce Committee, Subcommittee on Health, in regard to reauthorization of the Medical Device User Fee Act (MDUFA).
March 27, 2017

Testimony before Energy and Commerce Committee, Subcommittee on Health, on Examining FDA’s Medical Device User Fee Program

On March 28, Alliance for Aging Research Vice President of Public Policy Cynthia Bens testified before the United States House of Representatives' Energy and Commerce Committee, Subcommittee on Health, at its hearing on the FDA’s Medical Device User Fee Program.
March 22, 2017

Statement on Congressional Action to Reauthorize the FDA’s Prescription Drug and Medical Device User Fee Programs

Alliance for Aging Research Vice President of Public Policy Cynthia Bens issued the following statement regarding congressional action taken this week to begin consideration of the U.S. Food and Drug Administration’s (FDA) prescription drug and medical device user fee programs.
March 7, 2017

FY 2018 Labor, HHS, Education, and Related Agencies Appropriations Testimony from the Alliance

This is testimony from the Alliance for Aging regarding the Fiscal Year 2018 Labor, Health and Human Services, Education, and Related Agencies appropriations process. It notes that "there is an ever-increasing need for sustained investment in the NIH, CDC, and AHRQ. Our testimony will highlight critical health concerns that disproportionately affect older adults and initiatives supported by our federal health agencies that are addressing them."  
February 27, 2017

Letter to President Trump on Federal Public Health and Biomedical Research Workforce and Federal Hiring

The Alliance for Aging Research joined other organizations in calling on President Donald J. Trump to consider of the vital role of the federal public health and biomedical research workforce to the United States as he considers long-term policy regarding federal hiring.
January 24, 2017

Comments on Oversight Framework for Molecular Diagnostic Tests, including Laboratory Developed Tests (LDTs)/Senate Version

This letter to Senate Majority Leader Sen. Mitch McConnell and Senate Minority Leader Sen. Charles Schumer that urges them to "make updating the oversight framework for all molecular diagnostic tests, including laboratory developed tests (LDTs), a priority early in the 115th Congress." 
January 24, 2017

Comments on Oversight Framework for Molecular Diagnostic Tests, including Laboratory Developed Tests (LDTs)/House Version

This letter to House Speaker Rep. Paul Ryan and House Minority Speaker Rep. Nancy Pelosi urges them to "make updating the oversight framework for all molecular diagnostic tests, including laboratory developed tests (LDTs), a priority early in the 115th Congress."
January 19, 2017

Alliance and 90+ Organizations Urge Senate Committee Chairs to Safeguard U.S. Vaccine Policy during Price Confirmation Process

The Alliance has joined with more than 90 national organizations in urging the Senate to ensure Secretary of HHS nominee Tom Price, M.D., is committed to protecting U.S. citizens from vaccine preventable diseases.